Scarica l'app Stockscreener
203.35
2.08%
-4.33
Dopo l'orario di chiusura:
203.56
0.21
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$207.68
Aprire:
$205.85
Volume 24 ore:
810.18K
Relative Volume:
0.36
Capitalizzazione di mercato:
$43.59B
Reddito:
$742.00K
Utile/perdita netta:
$-1.37B
Rapporto P/E:
-28.75
EPS:
-7.0731
Flusso di cassa netto:
$-1.07B
1 W Prestazione:
-3.57%
1M Prestazione:
-1.75%
6M Prestazione:
+105.69%
1 anno Prestazione:
+402.72%
Intervallo 1D:
$202.59
$207.84
Intervallo di 1 settimana:
$202.59
$213.00
Portata 52W:
$42.18
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, MRNA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More. - Barron's
Morgan Stanley Initiates Overweight on RVMD, Highlighting RAS Pi - GuruFocus
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise - Seeking Alpha
RVMD Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus
RVMD Maintained by Stifel -- Price Target Raised to $230 - GuruFocus
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - The Manila Times
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal - finance.yahoo.com
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? - finance.yahoo.com
Revolution Medicines Got Its Breakthrough—What Moves It Next? - MarketBeat
Revolution’s Rasonque Shows Promise In Lung Cancer - insights.citeline.com
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today - Benzinga
Revolution Medicines(RVMD.US) Director Sells US$11.38 Million in Common Stock - Moomoo
RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM - GuruFocus
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - The Manila Times
Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC - Quiver Quantitative
An experimental lung cancer drug held disease in check for 89% of patients in one group. - Stock Titan
Revolution Medicines (RVMD) insider sale under preset trading plan - Stock Titan
Challenging Convention to Solve the Hardest Problems in Medicine – Revolution Medicines - Oncodaily
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals - BioSpace
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Enters Lease Agreements for New Headquarters in Redwood City - marketscreener.com
What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders - webull.com
New pancreatic cancer pill priced at $480,000 per year - KTLA
Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares - Stock Titan
Revolution’s newly approved drug doubles pancreatic cancer survival time - Mugglehead Investment Magazine
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions - Seeking Alpha
StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy - Genetic Engineering and Biotechnology News
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer - TradingView
Revolution Medicines (RVMD) Falls as Investors Appear to Take Profits After FDA Approval - Quiver Quantitative
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug - Benzinga
Revolution Medicines stock hits all-time high at 220.8 USD - Investing.com
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports - marketscreener.com
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - Barchart.com
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - Yahoo! Finance Canada
Revolution Medicines (RVMD) Gains FDA Approval for Rasonque, Sha - GuruFocus
US FDA approves Revolution Medicines' pancreatic cancer drug - marketscreener.com
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? - The Motley Fool
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Revolution Medicines (NASDAQ: RVMD) trust to sell 3,000 shares under Rule 144 - Stock Titan
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - AOL.com
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.62%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):